Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis

Yuzhou Zhu1,2 | Tinghan Yang1,2 | Qingbin Wu1,2 | Xuyang Yang1,2 | Jianqi Hao2 | Xiangbing Deng1,2 | Shuo Yang1,2 | Chaoyang Gu1,2 | Ziqiang Wang1,2

1Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
2West China Hospital, Sichuan University, Chengdu, Sichuan Province, China

Abstract

Liquid biopsy is a promising method in detecting colorectal cancer (CRC). However, previous meta-analyses only focused on the diagnostic performance of cell-free DNA (cfDNA). Therefore, we firstly evaluated the overall performance of all liquid biopsy methods. The pooled sensitivities, specificities, diagnostic odds ratios, and area under curve (AUC) of summary receiver operating characteristic curve for all liquid biopsy methods, exosomes, circulating tumor cells (CTCs), and cfDNA were calculated, respectively. A total of 62 articles involving 18 739 individuals were included. Fifty-one articles were about cfDNA, five articles were about CTCs, and six articles were about exosomes. The overall performance of all liquid biopsy methods had a pooled sensitivity, specificity, and AUC of 0.77 (95% confidence interval [CI] 0.76-0.78), 0.89 (95% CI 0.88-0.90), and 0.9004, respectively. The sensitivities were 0.82 (95% CI 0.79-0.85), 0.76 (95% CI 0.72-0.80), and 0.76 (95% CI 0.75-0.77) for CTCs, exosomes, and cfDNA, respectively. The specificities were 0.97 (95% CI 0.95-0.99), 0.92 (95% CI 0.89-0.94), and 0.88 (95% CI 0.87-0.89) for CTCs, exosomes, and cfDNA, respectively. The AUC were 0.9772, 0.9037, and 0.8963 for CTCs, exosomes, and cfDNA, respectively. The overall performance of all liquid biopsy methods had great diagnostic value in detecting CRC, regardless of subtypes. Among all liquid biopsy methods, CTCs showed the best diagnostic performance.

KEYWORDS

cell-free DNA, colorectal cancer, CTCs, exosomes, liquid biopsy

1 | INTRODUCTION

Colorectal cancer (CRC), characterized by its high lethality and morbidity, is the third most common cancer in the world.1 Data from the US Preventive Services Working Group indicate that if CRC could be diagnosed earlier, about 60% of CRC deaths could be averted, and the average 5-year survival rate could be raised from 46% to 73%.2 Therefore, early detection of CRC is the key to reduce mortality.3 Presently, colonoscopy is the gold standard for the diagnosis of CRC,4,5 which decreases mortality by 68% and incidence by 69%.6 However, the benefits of colonoscopy...
are not without a price, as it is invasive, with undesirable compliance and sometimes harmful to the patients.\textsuperscript{5} Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are blood-based markers in current clinical use, mainly for monitoring the response to treatment and progression of CRC. However, owing to low sensitivity and specificity, CEA and CA 19-9 have limited value in CRC detection.\textsuperscript{7}

In recent years, liquid biopsy is regarded as a method for cancer detection. Several methods have been used as liquid biopsy to detect biomolecules or cells in blood released from tumors, including cell-free DNA (cfDNA) (nucleic acid chains derived from various cell types, including but not limited to tumor cells),\textsuperscript{8} circulating tumor cell (CTCs) (cells fall off from primary cancer into blood or lymphatic vessels),\textsuperscript{9} and exosomes (vesicles secreted by cancer cells, with a diameter between 30 nm and 100 nm).\textsuperscript{10} Those methods are mini-invasive and could provide a representative sample of the whole tumor, which eliminates tumor heterogeneity.\textsuperscript{11} In the last decades, the diagnostic value of various liquid biopsy methods in detecting CRC has been extensively studied. However, all researches only evaluated diagnostic performance in single liquid biopsy method (cfDNA, CTCs, or exosomes). Currently, it is still under debate what the best liquid biopsy method is and what is the overall performance of all liquid biopsy methods. In the present study, we performed a meta-analysis to evaluate the diagnostic performance of CTCs, exosomes, and cfDNA and the overall performance of those methods in detecting CRC.

\section{Materials and Methods}

\subsection{Search strategy}

Two independent reviewers performed a systemic search on PubMed, EMBASE, Medline, and Web of science for eligible studies from 2002 to August 2019. The search strategy is shown in Table S1.

\subsection{Inclusion and exclusion criteria}

Potential articles were appraised by the reviewers independently based on the inclusion and exclusion criteria mentioned below. Any discrepancy was adjudicated by the third reviewer. The screening process was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendation.\textsuperscript{12}

Inclusion criteria: (a) human studies; (b) diagnostic studies reporting the absolute numbers of true-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN); and (c) the total number of patients and control group should be more than 20.

Exclusion criteria: (a) animal studies; (b) studies without sufficient data to build a 2 \times 2 contingency table; (c) prognostic studies; (d) article types were systematic reviews, meta-analysis, case-reports, and letters or comments.

\subsection{Quality assessment and data extraction}

Two reviewers evaluated the quality of each eligible article according to Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2)\textsuperscript{13} and extracted the following data from each included article: author, year of publication, sample size, country, control type, absolute numbers of TP, FP, FN, TN, measuring object, and assay methods. Sensitivity and specificity were then calculated. If more than one set was available in the same article, the set of data (TP, FP, FN, and TN) with highest area under curve (AUC) value was extracted.

\subsection{Statistical analysis}

Circulating tumor cells, exosomes, and cfDNA were the three major subtypes of liquid biopsy. Assay methods of cfDNA included measuring cfDNA level (CFD level), DNA integrity, and methylation of DNA. Pooled sensitivities (95\% confidence interval [CI]), pooled specificities (95\% CI), pooled positive likelihood ratio (PLR) (95\% CI), pooled negative likelihood ratio (NLR) (95\% CI), and pooled diagnostic odds ratio (DOR) for the overall performance of all liquid biopsy methods, CTCs, exosomes, and cfDNA were calculated using the bivariate model.\textsuperscript{14} These data were shown in both tabular form and in forest plots.

We used Spearman's correlation coefficient to evaluate the threshold effect and to assess heterogeneity among researches.\textsuperscript{15-17} A $P$ value less than .05 implied significant threshold effect with a negative correlation between specificity and sensitivity.\textsuperscript{18} We also adopted Higgins $I^2$ statistic to measure heterogeneity among researches. If $I^2$ was more than 50\%, which demonstrated substantial heterogeneity, random-effect model was adopted to integrate the data.\textsuperscript{20,22-24} Publication bias was evaluated by Deeks' funnel plots asymmetry test.\textsuperscript{25} A $P$ value less than .05 suggested statistically significant publication bias.\textsuperscript{25} All statistical analyses were completed using Stata 14.0 software (Stata Corporation) and Meta-disc 1.4 software (XI Cochrane Colloquium).\textsuperscript{26,27}

\section{Results}

\subsection{Study selection and description}

The initial search yielded 12 455 articles. After screening titles and abstracts, and removing duplications, the full text
of 256 articles was reviewed. Finally, 62 articles involving 18,739 individuals were included. 28-89: 51 articles were on cfDNA, 28-75,81-83 five articles were on CTCs, 76-80 and six articles were on exosomes. 84-89 The flow chart is summarized in Figure 1.

Cell-free DNA level, DNA integrity, and DNA methylation were the three different assay methods for cfDNA. Among the 51 studies on cfDNA, 28-75,81-83 11 measured CFD level, 28-35,57,58,60 four measured DNA integrity, 57-60 and 36 measured DNA methylation. 36-56,61-75 Three articles measured both DNA integrity and CFD level. 57,58,60 For DNA methylation, 21 focused on the methylation of SEPT9, 36-56 and 15 were on the methylation of other sites. 61-75 Basic characteristics of all 62 included studies are shown in Table S2.

3.2 | Quality assessment

Methodology quality of 62 included studies was evaluated by QUADAS-2 quality assessment tool and shown in Figure S1. Study quality was generally acceptable, varying from moderate to high.
3.3 | Heterogeneity

Spearman’s correlation coefficient was used to evaluate the threshold effect among researches. The $P$ value was .567, revealing that no significant threshold effect existed. DOR was an appropriate balance between sensitivity and specificity, and we used Higgins $I^2$ of DOR to evaluate heterogeneity among studies. $I^2$ of DOR for all liquid biopsy methods was 78.1%.

3.4 | Diagnostic performance for all liquid biopsy methods in detecting CRC

$I^2$ more than 50% showed that significant heterogeneity existed among studies; therefore, random-effect model was adopted to pool data. The pooled sensitivity, specificity, PLR, NLR, and DOR for overall performance of all liquid biopsy methods in detecting CRC were 0.77 (95% CI 0.76-0.78), 0.89 (95% CI 0.88-0.90), 7.37 (95% CI 6.17-8.81), 0.27 (95% CI 0.24-0.31), and 30.28 (95% CI 23.82-38.50), respectively. Summary receiver operating characteristic curve (SROC) was drawn and liquid biopsy yielded an AUC of 0.9004. The results are shown in Table 1 and Figure S2.

3.5 | Diagnostic performance for CTCs in detecting CRC

Five of all included articles were on CTCs. The pooled sensitivity, specificity, PLR, NLR, and DOR were 0.82 (95% CI 0.79-0.85), 0.97 (95% CI 0.95-0.99), 23.80 (95% CI 13.41-42.24), 0.20 (95% CI 0.10-0.37), and 159.99 (95% CI 72.38-353.67), respectively. The AUC was 0.9772 (Table 1; Figure S3).

3.6 | Diagnostic performance for exosomes in detecting CRC

Six articles were on exosomes. The pooled sensitivity, specificity, PLR, NLR, and DOR were 0.76 (95% CI 0.72-0.80), 0.94 (95% CI 0.91-0.97), 8.95 (95% CI 4.36-18.39), 0.28 (95% CI 0.25-0.33), and 33.83 (95% CI 12.93-88.47), respectively. The AUC was 0.9037. (Table 1; Figure S4).

3.7 | Diagnostic performance for cfDNA in detecting CRC

After pooling 51 studies on cfDNA, the pooled sensitivity, specificity, PLR, NLR, and DOR were 0.76 (95% CI 0.75-0.77), 0.88 (95% CI 0.87-0.89), 6.20 (95% CI 5.17-7.45), 0.27 (95% CI 0.24-0.31), and 23.98 (95% CI 18.74-30.69), respectively. Cell-free DNA yielded an AUC of 0.8963 (Table 1; Figure S5).

| Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC for SROC |
|----------------------|----------------------|-------------|-------------|-------------|--------------|
| All liquid biopsy methods | 0.77(0.76-0.78) | 0.89(0.88-0.90) | 7.37(6.17-8.81) | 0.27(0.24-0.31) | 30.28(23.82-38.50) | 0.9004 |
| CTCs | 0.82(0.79-0.85) | 0.97(0.95-0.99) | 23.80(13.41-42.24) | 0.20(0.10-0.37) | 159.99(72.38-353.67) | 0.9772 |
| Exosomes | 0.76(0.72-0.80) | 0.92(0.89-0.94) | 7.17(4.00-12.87) | 0.24(0.16-0.36) | 27.67(12.94-59.15) | 0.9037 |
| Overall cfDNA | 0.76(0.75-0.77) | 0.88(0.87-0.89) | 6.20(5.17-7.45) | 0.28(0.25-0.33) | 23.98(18.74-30.69) | 0.8963 |
| CFD level | 0.77(0.74-0.80) | 0.92(0.90-0.94) | 8.85(4.04-19.36) | 0.29(0.20-0.43) | 33.83(12.93-88.47) | 0.8838 |
| DNA integrity | 0.71(0.66-0.76) | 0.94(0.91-0.97) | 8.95(4.36-18.39) | 0.32(0.21-0.47) | 31.40(11.87-83.10) | 0.9187 |
| DNA methylation | 0.76(0.75-0.77) | 0.88(0.87-0.89) | 6.20(5.17-7.45) | 0.28(0.25-0.33) | 23.98(18.74-30.69) | 0.8963 |
| Methylation of SEPT9 | 0.74(0.72-0.76) | 0.87(0.86-0.88) | 6.70(5.34-8.39) | 0.31(0.26-0.35) | 24.44(17.67-33.82) | 0.8976 |
| Methylation of other sites | 0.78(0.76-0.80) | 0.89(0.88-0.90) | 5.54(4.02-7.64) | 0.27(0.20-0.36) | 22.58(15.09-33.78) | 0.8940 |

Abbreviations: AUC, area under curve; NLR, negative likelihood ratio; PLR, positive likelihood ratio.
6.70 (95% CI 5.34-8.39), 0.31 (95% CI 0.26-0.35), 24.44 (95% CI 17.67-33.82), and 0.8976, respectively (Table 1; Figure S9). Fifteen articles were about the other methylation sites,61-75 with pooled sensitivity, specificity, PLR, NLR, DOR, and AUC of 0.78 (95% CI 0.76-0.80), 0.89 (95% CI 0.88-0.90), 5.54 (95% CI 4.02-7.64), 0.27 (95% CI 0.20-0.36), 22.58 (95% CI 15.09-33.78), and 0.8940, respectively (Table 1; Figure S10).

3.8 Publication bias

Publication bias was assessed by the \( P \) value of Deeks’ funnel plot asymmetry test. The \( p \) value was 0.94, revealing that publication bias was not significant. The result of Deeks’ funnel plot asymmetry test is shown in Figure S11.

4 DISCUSSION

This meta-analysis included 62 articles on liquid biopsy involving 18,739 individuals; the pooled sensitivity and specificity for all liquid biopsy methods were 0.77 (95% CI 0.76-0.78) and 0.89 (95% CI 0.88-0.90), respectively. The AUC of SROC for all liquid biopsy methods was 0.9004 and revealed high diagnostic value, suggesting liquid biopsy was a powerful diagnostic tool for CRC.

A series of tumor markers have been associated with CRC, particularly CEA. However, all these markers have a poor diagnostic performance in detecting CRC because of significant overlap with benign disease and low sensitivity for early stage disease.90 A meta-analysis concluded that the pooled sensitivity for CEA in detecting CRC was only 46% (95% CI 0.45-0.47).90 No other tumor marker have a higher diagnostic sensitivity, including CA 19-9 (pooled sensitivity 0.30, 95% CI 0.28-0.32). Furthermore, there is also limitation in the specificity of CEA, which was reported to be 89% (95% CI 0.88-0.92).90 Gastritis, liver disease, diverticulitis, peptic ulcer disease, diabetes, and any acute or chronic inflammatory state could all contribute to an elevated CEA level. Moreover, CEA levels are significantly higher in cigarette smokers than in nonsmokers.91 Compared with them, liquid biopsy has the same degree of invasion to patients, but a much better diagnostic performance (pooled sensitivity 0.77, 95% CI 0.76-0.78; pooled specificity 0.89, 95% CI 0.88-0.90).

Fecal occult blood test (FOBT) and fecal immunohistochemistry test (FIT) are adopted in CRC screening. The FOBT has a sensitivity less than 50%.92 Aversion to handling stool is a cause for the low uptake of the fecal test, as only 58% of patients who are sent the FOBT return a sample. The pooled sensitivity for FIT was 0.79 (95% CI 0.69-0.86) and specificity was 0.94 (95% CI 0.92-0.95).92 Compared with liquid biopsy, FIT could be FP due to an upper gastrointestinal bleed that is large enough for hemoglobin to escape degradation during transit.92 Moreover, for early stage CRC, because there is usually no hemorrhage, the sensitivity and specificity for FIT are much lower, and have been estimated as 25%-56% for sensitivity and 68% to 96% for specificity.92

Invasive and localized tumors may transfer CTCs into the bloodstream before obvious metastasis occurs, which indicates that individual detection of CTCs is more important. Circulating tumor cells are mainly detected based on transcriptome or epithelial markers.93 The former analyses CRC-derived CTCs through quantification of reverse transcription PCR (qRT-PCR), while the later through epithelial markers, such as EpCAM and cytokeratins, that are not expressed in the ambient mesenchymal blood cells.79 The lack of standardized process of blood collection, biomarkers extraction, isolation, and final analysis contributed to the variance of sensitivity for CTCs in detecting CRC,77 which varied from 0.65 to 0.94 in the present study. As CTCs have a short life into the bloodstream, being quickly detected and destroyed in the liver by natural killer, the sensitivity of CTC was lower than its specificity.76 Compared with qRT-PCR-based methods, EpCAM-based methods presented lower sensitivity but higher specificity: On one hand, EpCAM-based methods could not detect the whole CTCs, since cells expressing low levels of epithelial markers could not be recognized by the capture reagent.94 However, small changes at transcriptome could still be detected easily by qRT-PCR.95 On the other hand, EpCAM-based methods detected CTCs on a series of tumor-specific epithelial markers, which contributed to the high specificity.94 Even so, CTCs appeared to have highest sensitivity and specificity compared with cfDNA and exosomes, since patients with various benign inflammatory colon diseases also harbor viable cfDNA fragments or exosomes which could be detected through cfDNA or exosome-based methods, leading to FP results.28

Exosomes are membrane microvesicles that are released by tumor cells and circulate in body fluids.95 CRC cells secrete significantly more exosomes than normal cells.89 These tumor-derived exosomes could promote the transfer of small molecules, such as growth factors, chemokines, and DNA.87 Therefore, detecting exosomes in blood samples is a practicable method for CRC diagnosis. Besides, exosomes are stable at room temperature for a long time.84 Furthermore, protein markers of these exosomes could be adopted to predict future organ metastasis.85 In the present study, the pooled sensitivity, specificity, and AUC of exosomes were 0.76 (95% CI 0.72-0.80), 0.92 (95% CI 0.89-0.94), and 0.9037. The results showed that exosomes had a robust specificity, but the sensitivity was relatively low. Exosomes could transfer various bioactive molecules (such as proteins, lipids, and microRNA) from donor cells to recipient cells.84 The communication of substance and information between cancer cells was tight requiring special signal.
transmission and possibly secreting some special substances, which could contribute to the high specificity. 

Compared with exosomes and CTCs, cfDNA had the lowest specificity. The possible reasons could be as follows: (a) cfDNA derived from various cell types, including but not limited to tumor cells; and (b) some articles took patients with polyps as control groups. Compared with healthy individuals, cell necrosis increased in polyps, which also led to an increase in cfDNA level. Nevertheless, the AUC of SROC for overall cfDNA was 0.8963, indicating cfDNA still had high diagnostic efficiency. A previous meta-analysis tried to evaluate the diagnostic value of cfDNA; however, it only focused on cfDNA without mutation and methylation gene, and included 14 articles in total. It showed that cfDNA had a sensitivity, specificity, and AUC of 0.735 (95% CI 0.713-0.757), 0.918 (95% CI 0.900-0.934), and 0.8818, respectively. Our research included cfDNA measured by CFD level, DNA integrity, and DNA methylation, revealing that cfDNA had higher diagnostic performance.

Cell-free DNA was measured based on CFD level, DNA integrity, and DNA methylation. The sizes of cfDNA fragments discharged by necrotic tumor cells were different and longer, while the lengths of cfDNA fragments discharged by apoptotic nontumor cells were the same and shorter, ranging from 185 to 200 base pairs. Cell-free DNA level was defined as relative or absolute concentration of all cfDNA, mainly the concentration of ALU115, which represented total cfDNA (long fragments and short fragments). ALU247 represented tumor cfDNA (long fragments). Integrity index calculated the ratio of ALU247 to ALU115, representing tumor cfDNA (long fragments). DNA integrity was perhaps the best for CRC detection with the highest AUC (0.9187 vs 0.8838 [CFD] vs 0.8963 [DNA methylation]). However, it seemed to be less sensitive for CRC compared to the other two methods. CFD level was perhaps the best for CRC screening with highest sensitivity (0.77 vs 0.71 [DNA integrity] vs 0.76 [DNA methylation]). Generally, CFD level had a worse diagnostic value than DNA integrity, since apoptotic nontumor cells could also increase CFD level. Previous research demonstrated higher cfDNA concentration in patients with late-stage diseases. This advantage indicated that cfDNA could be used for the follow-up of metastatic CRC patients during treatment.

Colorectal cancer could be determined by detecting DNA methylation level of several gene sites, SEPT9 is one of the most common sites. CpG island in the promoter region of V2 transcript of SEPT9 gene was usually hypermethylated in CRC, which was adopted as detection markers. Although Song et al. published a meta-analysis on the performance of SEPT9 gene methylation in CRC diagnosis, their study had several limitations: (a) included fewer articles; (b) some of the included articles had poor quality; and (c) did not compare diagnostic performance of SEPT9 methylation and methylation on other sites. Our results showed that the diagnostic performance of methylation on SEPT9 was similar to methylation on other sites.

There were three meta-analyses focused on the diagnostic performance of cfDNA; nevertheless, compared to them, our research had some advantages: (a) we not only focused on the diagnostic value of cfDNA, but also focused on the diagnostic value of CTCs, exosomes, and overall performance of all liquid biopsy methods; (b) we compared diagnostic performance of CTCs, exosomes, and cfDNA; and (c) we included much more articles.

Our meta-analysis had several limitations. Firstly, as shown in Table 1, CTCs, exosomes, and cfDNA were the three major subtypes of liquid biopsy, while assay methods of cfDNA included measuring CFD level, DNA integrity, and methylation of DNA. These contributed to the heterogeneity for overall performance of all liquid biopsy. Secondly, the number of studies on CTCs and exosomes was much smaller than on cfDNA, which may introduce bias. Thirdly, only studies published in full text in English were included. Therefore, we only integrated sensitivity, specificity, PLR, NLR, and DOR of CTCs. Fourthly, unpublished studies were not included.

## 5 CONCLUSIONS

This meta-analysis concluded that liquid biopsy was a powerful diagnostic tool in detecting CRC with high sensitivity and specificity, which had great potential for clinic application. Among all liquid biopsy methods, CTCs showed the best diagnostic performance with the highest AUC.

## ACKNOWLEDGMENTS

The work is supported by the Department of Science and Technology of Sichuan Province no. 2018RZ0091.

## CONFLICT OF INTEREST

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## AUTHOR CONTRIBUTIONS

Yuzhou Zhu and Tinghan Yang contributed equally to this article. Yuzhou Zhu designed the project, developed the search strategy, and wrote the manuscript. Tinghan Yang checked the search, and reviewed the manuscript. Qingbin Wu and Xuyang Yang performed literature screening and data extraction. Jianqi Hao and Xiangbing Deng conducted the quality assessment of the included studies. Shuo Yang...
and Chaoyang Gu carried out the data analysis. Ziqiang Wang reviewed the manuscript and finally approved the version to be published.

**DATA AVAILABILITY STATEMENT**
This literature is a meta-analysis. The original contributions presented in the study are included in the article/Supporting information, further inquiries can be directed to the corresponding author wangziqiang@scu.edu.cn.

**ORCID**
Ziqiang Wang https://orcid.org/0000-0002-0415-2699

**REFERENCES**

1. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(3):145–164.

2. Berger BM, Parton MA, Levin B. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing. *Am J Manag Care*. 2016;22(2):e77–e81.

3. Uri L, Jason AD, Charles K, Robert ES. Strategies for Colorectal Cancer Screening. *Gastroenterology*. 2020;158(2):418–432.

4. Vatandoost N, Ghanbari J, Mojaver M, et al. Early detection of colorectal cancer: from conventional methods to novel biomarkers. *J Cancer Res Clin Oncol*. 2016;142(2):341–351.

5. Heiss JA, Brenner H. Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting. *Clin Epigenetics*. 2017;9:24.

6. Brenner H, Stock C, Hoffmeister M. Colorectal cancer screening: the time to act is now. *BMJ*. 2015;313:262.

7. Wise J. New bowel cancer screening test is recommended for England. *BMJ*. 2016;352:i273.

8. Petit J, Carroll G, Gould T, Pockney P, Dun M, Scott RJ. Cell-free DNA as a diagnostic blood-based biomarker for colorectal cancer: a systematic review. *J Surg Res*. 2019;236:184-197.

9. Riquet M, Rivera C, Gibault L, et al. Lymphatic spread of lung cancer: anatomical lymph node chains unchained in zones. *Rev Pneumol Clin*. 2014;70(1-2):16-25.

10. Palanisamy V, Sharma S, Deshpande A, Zhou H, Gmiezewski J, Wong DT. Nanostructural and transcriptomic analyses of human saliva derived exosomes. *PLoS One*. 2010;5(1):e5877.

11. Cheung AH, Chow C, To KF. Latest development of liquid biopsy. *J Thorac Dis*. 2018;10(Suppl 14):S1645-S1651.

12. Tam WWS, Tang A, Woo B, Goh SYS. Perception of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement of authors publishing reviews in nursing journals: a cross-sectional online survey. *BMJ Open*. 2019;9(4):e026271.

13. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2015;15:58(8):529-536.

14. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol*. 2005;58(10):982-990.

15. Wang X, Shi QX, Zeng PW, Mo FM, Chen ZH. Circulating cell free DNA as the diagnostic marker for colorectal cancer: a systematic review and meta-analysis. *Oncotarget*. 2018;9(36):24514-24524.

16. Song Z, Wang S, Liu Y. The diagnostic accuracy of liquid exosomes for lung cancer detection: a meta-analysis. *OncoTargets Ther*. 2019;12:181-192.

17. Sedgwick P. Spearman’s rank correlation coefficient. *BMJ*. 2014;349:g7327.

18. Hamza TH, Arends LR, van Houwelingen HC, Stijnen T. Multivariate random effects meta-analysis of diagnostic tests with multiple thresholds. *BMJ Med Res Methodol*. 2009;9:73.

19. Eng KA, Abadeh A, Ligocki C, et al. Acute appendicitis: a meta-analysis of the diagnostic accuracy of US, CT, and MRI as second-line imaging tests after an initial US. *Radiology*. 2018;288(3):717-727.

20. Jp H, Sg T, Jj D, Dg A. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560.

21. Maffione AM, Lopci E, Bluelme C, Giammarel F, Herrmann K, Rubello D. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. *Eur J Nucl Med Mol Imaging*. 2015;42(1):152-163.

22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560.

23. Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. *Gynecol Obstet Invest*. 2017;82(3):209-222.

24. Luo Y, She DL, Xiong H, Yang L, Fu SJ. Diagnostic value of liquid-based cytology in urothelial carcinoma diagnosis: a systematic review and meta-analysis. *PLoS One*. 2015;10(8):e0134940.

25. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol*. 2005;58(9):882-893.

26. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. MetaDiSc: a software for meta-analysis of test accuracy data. *BMJ Res Methodol*. 2006;6:31.

27. Kontopantelis E, Reeves D. Performance of statistical methods for meta-analysis when true study effects are non-normally distributed: a comparison between DerSimonian-Laird and restricted maximum likelihood. *Stat Methods Med Res*. 2012;21(6):657-659.

28. Agostini M, Pucciarelli S, Enzo MV, et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. *Ann Surg Oncol*. 2018;15(9):2461-2468.

29. Berger AW, Schwerdel D, Welz H, et al. Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. *PLoS One*. 2017;12(3):e0174308.

30. Czeiger D, Shaked G, Eini H, et al. Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. *Am J Clin Pathol*. 2011;135(2):264-270.

31. Danese E, Montagnana M, Minicocci AM, et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. *Clin Chem Lab Med*. 2010;48(11):1665-1668.
32. Flamini E, Mercatali L, Nanni O, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. *Clin Cancer Res*. 2006;12(23):6985-6988.

33. Lan Y-T, Chen M-H, Fang W-L, et al. Clinical relevance of cell-free DNA in gastrointestinal tract malignancy. *Oncotarget*. 2017;8(2):3009-3017.

34. Leszinski G, Lehner J, Gezer U, Holdenrieder S. Increased DNA integrity in colorectal cancer. *vivo (Athens, Greece)*. 2014;28(3):299-303.

35. Qi J, Qian C, Shi W, et al. Ala-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer. *Clin Biochem*. 2013;46(1-2):64-69.

36. Ahlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. *Clin Gastroenterol Hepatol*. 2012;10(3):272-277.

37. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. *Gut*. 2014;63(2):317-325.

38. deVos T, Tetznner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. *Clin Chem*. 2009;55(7):1337-1346.

39. Fu BO, Yan P, Zhang S, et al. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. *Dis Markers*. 2018;2018:1-11.

40. Grützmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. *PLoS One*. 2008;3(11):e3759.

41. He NA, Song L, Kang Q, et al. The pathological features of colorectal cancer determine the detection performance on blood ctDNA. *Technol Cancer Res Treat*. 2018;17:1533033818791794.

42. He Q, Chen HY, Bai EQ, et al. Development of a multiplex MethyLight assay for the detection of multimcogene methylation in human colorectal cancer. *Cancer Genet Cytogenet*. 2010;202(1):1-10.

43. Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. *J Gastroenterol Hepatol*. 2015;30(5):830-833.

44. Johnson DA, Barclay RL, Mergener K, et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. *PLoS One*. 2014;9(6):e98238.

45. Kang Q, Jin P, Yang L, et al. Significance of Septin9 gene methylation detection of plasma circulation DNA in colorectal cancer screening. *Zhonghua yi xue za zhi*. 2014;94(48):3839-3841.

46. Liu Y, Tham CK, Ong SY, et al. Serum methylation levels of TAC1, SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study. *Biomarkers*. 2013;18(5):399-405.

47. Lofton-Day C, Model F, DeVos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. *Clin Chem*. 2008;54(2):414-423.

48. Orntoft MB, Nielsen HJ, Orntoft TF, Andersen CL. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study. *BMJ Cancer*. 2015;15:819.

49. Potter NT, Hurban P, White MN, et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. *Clin Chem. 2014;60(9):1183-1191.*

50. Song L, Li Y, Jia J, et al. Algorithm optimization in methylation detection with multiple RT-qPCR. *PLoS One*. 2016;11(11):e0163333.

51. Sun J, Fei F, Zhang M, et al. The role of (m)SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. *BMC Cancer*. 2019;19(1):450.

52. Tänzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. *PLoS One*. 2015;5(2):e9061.

53. Töth K, Sipos F, Kalmár A, et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. *PLoS One*. 2012;7(9):e46000.

54. Töth K, Wasserkort R, Sipos F, et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. *PLoS One*. 2014;9(12):e115415.

55. Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. *BMC Med*. 2011;9:133.

56. Wu D, Zhou G, Jin P, et al. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening. *The Journal of molecular diagnostics : JMD*. 2016;18(4):535-545.

57. El-Gayar D, El-Abd N, Hassan N, Ali R. Increased free circulating DNA integrity index as a serum biomarker in patients with colorectal carcinoma. *Asian Pac J Cancer Prev*. 2016;17(3):939-944.

58. Hao TB, Shi W, Shen XJ, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. *Br J Cancer*. 2014;111(8):1482-1489.

59. Nagai Y, Sunami E, Yamamoto Y, et al. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. *Oncotarget*. 2017;8(7):11906-11916.

60. Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. *Clin Chem*. 2006;52(6):1062-1069.

61. Herbst A, Rahimig K, Stieber P, et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. *Am J Gastroenterol*. 2011;106(6):1110-1118.

62. Tang D, Liu J, Wang D-R, Yu H-F, Li Y-K, Zhang J-Q. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. *Clin Invest Med*. 2011;34(2):88-95.

63. Cassinotti E, Melson J, Liggett T, et al. DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. *Int J Cancer*. 2012;131(5):1153-1157.

64. Sakamoto J, Fujiya M, Okamoto K, et al. Immunoprecipitation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients. *BMC Cancer*. 2014;14:215.

65. ZHU et al. ""
78. Tsai W-S, Nimgaonkar A, Segurado O, et al. Prospective clinical study of circulating tumor cells for colorectal cancer screening. J Clin Oncol. 2005;43(2):127-132.

79. Wang J-Y, Yeh C-S, Chen Y-F, et al. Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells and microemboli for cancer detection. J Mol Diagn. 2015;17(5):737-747.

80. Wong S, Ng SSM, Cheung MT, et al. Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. Br J Cancer. 2011;104(6):1000-1006.

81. Molparia B, Oliveira G, Wagner JL, Spencer EG, Torkamani A. A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection. PLoS One. 2018;13(5):e0196826.

82. Borchers R, Heinzlmann M, Zahn R, et al. K-ras mutations in sera of patients with colorectal neoplasias and long-standing inflammatory bowel disease. Scand J Gastroenterol. 2002;37(6):715-718.

83. Valladares-Ayerbes M, Blanco-Calvo M, Reboredo M, et al. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer. Int J Mol Sci. 2012;13(4):4367-4387.

84. Graham LD, Pedersen SK, Brown GS, et al. Colorectal Neoplasia Differentially Expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes Cancer. 2011;2(8):829-840.

85. Liu T, Zhang X, Gao S, et al. Exosomal long noncoding RNA CRNDE has a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget. 2016;7(51):85551-85563.

86. Liu X, Pan B, Sun LL, et al. Circulating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancer. Clin Cancer Res. 2018;24(7):1846-1854.

87. Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9(4):e92921.

88. Sun BO, Li Y, Zhou Y, et al. Circulating exosomal CPNE3 as a diagnostic and prognostic biomarker for colorectal cancer. J Cell Physiol. 2019;234(2):1416-1425.

89. Uratani R, Toyama Y, Kitajima T, et al. Diagnostic potential of cell-free and exosomal microRNAs in the identification of patients with high-risk colorectal adenomas. PLoS One. 2016;11(10):e0160722.

90. Liu Z, Zhang Y, Niu Y, et al. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. PLoS One. 2014;9(8):e103910.

91. Sajid KM, Parveen R, Durr ES, et al. Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers. J Pak Med Assoc. 2007;57(12):595-599.

92. Werner S, Krause F, Rolny V, et al. Evaluation of a 5-marker blood test for colorectal cancer early detection in a colorectal cancer screening setting. Clin Cancer Res. 2016;22(7):1725-1733.

93. Augestad KM, Merok MA, Ignatovic D. Tailored treatment of colorectal cancer: surgical, molecular, and genetic considerations. Clin Med Insights Oncol. 2017:11:1779554917690766.

94. Nicolazzo C, Raimondi C, Francescangeli F, et al. EpCAM-expressing circulating tumor cells in colorectal cancer. Int J Biol Markers. 2017;32(4):e415-e420.

95. Beach A, Zhang HG, Ratajczak MZ, Kakar SK. Exosomes: an overview of biogenesis, composition and role in ovarian cancer. J Ovarian Res. 2014;7:14.

96. Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015;219:278-294.

97. Mangano A, Mangano A, Lianos GD, et al. Circulating free DNA methylation in colorectal cancer is restricted to a single CpG island. Cancer Med. 2020;9:5699–5707. https://doi.org/10.1002/cam4.3276

98. Wasserkort R, Kalmar A, Valcz G, et al. Aberrant septin 9 DNA methylation assay and a comparison with other CRC screening tests: a meta-analysis. How to cite this article: Zhu Y, Yang T, Wu Q, et al. Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis. Cancer Med. 2020;9:5699–5707. https://doi.org/10.1002/cam4.3276

99. Ebert MPA, Model F, Mooney S, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology. 2006;131(5):1418-1430.

100. Oh TaeJeong, Kim N, Moon Y, et al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn. 2013;15(4):498-507.

101. Kostin PA, Zakharzhevskaia NB, Generozov EV, Govorun VM, Chernyshov SV, Shchelygin A. Hypermethylation of the CDH1, SEPT9, HLF and ALX4 genes and their diagnostic significance in colorectal cancer. Vopr Onkol. 2010;56(2):162-168.

102. Melotte V, Yi JM, Lentjes M, et al. Spectrin repeat containing protein 5 methylation is a potential noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol. 2015;21(9):2629-2637.

103. Chen JY, Tsai WS, Shao HJ, et al. Sensitive and specific bio-mimetic lipid coated microfluidics to isolate viable circulating tumor cells and microemboli for cancer detection. PLoS One. 2017;12(7):e0180809.

104. Douard R, Moutereau S, Serru V, et al. Immunobead multiplex RT-PCR detection of carcinoembryonic genes expressing cells in the blood of colorectal cancer patients. Clin Chem Lab Med. 2005;43(2):127-132.

105. Tsai W-S, Nimgaonkar A, Segurado O, et al. Prospective clinical study of circulating tumor cells for colorectal cancer screening. J Clin Oncol. 2018;36(4_suppl):556.

106. Wang J-Y, Yeh C-S, Chen Y-F, et al. Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer. Int J Mol Med. 2006;17(5):737-747.

107. Wang J-Y, Yeh C-S, Chen Y-F, et al. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer. Int J Mol Sci. 2012;13(4):3467-3487.

108. Graham LD, Pedersen SK, Brown GS, et al. Colorectal Neoplasia Differentially Expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes Cancer. 2011;2(8):829-840.

109. Liu T, Zhang X, Gao S, et al. Exosomal long noncoding RNA CRNDE has a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget. 2016;7(51):85551-85563.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Zhu Y, Yang T, Wu Q, et al. Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis. Cancer Med. 2020;9:5699–5707. https://doi.org/10.1002/cam4.3276